The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.
The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.
The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.
NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.
The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback